Eliem Therapeutics Inc

NASDAQ ELYM

Download Data

Eliem Therapeutics Inc Price to Tangible Book Ratio (P/TB) on June 03, 2024

Eliem Therapeutics Inc Price to Tangible Book Ratio (P/TB) is NA on June 03, 2024, a NA change year over year. The price to tangible book ratio compares the market price per share of a company's stock to its tangible book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus goodwill and intangible assets, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's tangible assets relative to its market price. A higher ratio suggests that investors are willing to pay a higher price for each unit of tangible book value, indicating positive market sentiment.
  • Eliem Therapeutics Inc 52-week high Price to Tangible Book Ratio (P/TB) is NA on June 03, 2024, which is NA below the current Price to Tangible Book Ratio (P/TB).
  • Eliem Therapeutics Inc 52-week low Price to Tangible Book Ratio (P/TB) is NA on June 03, 2024, which is NA below the current Price to Tangible Book Ratio (P/TB).
  • Eliem Therapeutics Inc average Price to Tangible Book Ratio (P/TB) for the last 52 weeks is NA.
NASDAQ: ELYM

Eliem Therapeutics Inc

CEO Mr. Robert W. Azelby M.B.A.
IPO Date Aug. 10, 2021
Location United States
Headquarters 23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees 9
Sector Healthcare
Industry Biotechnology
Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

CYT

Cyteir Therapeutics Inc

NA

NA

IPSC

Century Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email